Akihito Kawazoe, Syed Mohammad Ali Kazmi, Rui-Hua Xu, Thomas Jemielita, Ken Hatogai, David Eli Adelberg, Josep Tabernero. "KANDLELIT-012: Phase 3 study of MK-1084 (a
                    <i>KRAS G12C</i>
                    inhibitor) plus cetuximab and mFOLFOX6 with or without bevacizumab for
                    <i>KRAS</i>
                    <i>G12C</i>
                    -mutant colorectal cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.2_suppl.tps267